Deals this week: Becton, Dickinson and Co, Earlens, AstraZeneca

8 June 2017 (Last Updated June 8th, 2017 18:30)

US-based Becton, Dickinson and Co (BD) has announced seven underwritten public offerings of notes to raise $10.463bn.

US-based Becton, Dickinson and Co (BD) has announced seven underwritten public offerings of notes to raise $10.463bn.

The notes carry interest rates of 0.368% (due June 2019), 2.133% (due June 2019), and 2.404% (due June 2020). They also have rates of 2.894% (due June 2022), floating rate (due June 2022), 3.363% (due June 2024), 3.700% (due June 2027), and 4.669% (due June 2047).

Earlens Corp has announced the private placement of Series C preferred stock in order to raise $73m.

Vertex Healthcare subscribed to the placement along with participation from Cochlear Ltd, CRG, Richard King Mellon Foundation, Windham Venture Partners, and others.

The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities.

The UK-based biopharmaceutical company AstraZeneca plc has announced three public offerings of senior notes, including floating rate senior notes to raise gross proceeds of $2bn.

The notes bear interest rates of 2.375% and 3.125%, which are due to mature in 2022 and 2027, respectively.

"The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities."

AstraZeneca plans to use the funds for general corporate purposes.

2bPrecise LLC has signed a technology licensing agreement with non-profit medical research group, Mayo Clinic, to develop genomics-based clinical decision support protocols.

As part of the agreement, 2bPrecise will incorporate the new protocols to measure results in patients affected with cardiovascular genetic disease.

2bPrecise is a provider of cloud-based precision medicine platform and is based in the US.

Trice Medical Inc has announced the raising of $19.3m in a series C venture financing round.

The US-based orthopaedic diagnostics devices developer plans to use the funds to expand its presence in the US market.